[1]李蕴智,安洋,成艾璇,等.玻璃体切割术后糖尿病黄斑水肿治疗新进展[J].眼科新进展,2023,43(3):249-252.[doi:10.13389/j.cnki.rao.2023.0051]
　LI Yunzhi,AN Yang,CHENG Aixuan,et al.Recent research advances in the treatment of diabetic macular edema after vitrectomy[J].Recent Advances in Ophthalmology,2023,43(3):249-252.[doi:10.13389/j.cnki.rao.2023.0051]
点击复制

玻璃体切割术后糖尿病黄斑水肿治疗新进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
43卷
期数:
2023年3期
页码:
249-252
栏目:
文献综述
出版日期:
2023-03-05

文章信息/Info

Title:
Recent research advances in the treatment of diabetic macular edema after vitrectomy
作者:
李蕴智; 安洋; 成艾璇; 芦志雯; 范斌
130041　吉林省长春市，吉林大学第二医院眼科
Author(s):
LI Yunzhi; AN Yang; CHENG Aixuan; LU Zhiwen; FAN Bin
Department of Ophthalmology，the Second Hospital of Jilin University,Changchun 130041,Jilin Province,China
关键词:
糖尿病黄斑水肿; 玻璃体切割术; 抗血管内皮生长因子; 糖皮质激素; 阈值下微脉冲激光
Keywords:
diabetic macular edema;  vitrectomy;  anti-vascular endothelial growth factor;  glucocorticoids;  subthreshold micropulse laser
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2023.0051
文献标志码:
A
摘要:
糖尿病黄斑水肿（DME）是糖尿病视网膜病变（DR）常见的并发症，而DR患者常因玻璃体积血和视网膜脱离等并发症需要行玻璃体切割术，术后DME的治疗方案随着玻璃体内替代物和药物动力学的改变发生变化，目前该病主要的治疗方案有抗血管内皮生长因子药物、糖皮质激素和阈值下微脉冲激光等。本文就玻璃体切割术后DME的治疗进展进行综述。
Abstract:
Diabetic macular edema (DME) is a common complication of diabetic retinopathy (DR). DR patients need vitrectomy because of complications such as vitreous hemorrhage and retinal detachment. The treatment of DME after vitrectomy changes with the changes in vitreous substitutes and pharmacokinetics. At present, the main treatments include anti-vascular endothelial growth factor drugs, glucocorticoids and subthreshold micropulse laser. This article will review the progress in the treatment of DME after vitrectomy.

参考文献/References:

［1］　ACN D,WU L.Multimodal imaging in diabetic macular edema［J］．Asia Pac J Ophthalmol (Phila),2018,7(1):22-27.
［2］　WHITE N H,SUN W,CLEARY P A,TAMBORLANE W V,DANIS R P,Hainsworth D P,et al.Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC:comparison of adults and adolescents［J］．Diabetes,2010,59(5):1244-1253.
［3］　KULIKOV A N,SOSNOVSKII S V,BEREZIN R D,MALTSEV D S,OSKANOV D H,GRIBANOV N A.Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy:an optical coherence tomography study［J］．Clin Ophthalmol,2017,11:1995-2002.
［4］　PESSOA B,DIAS D A,BAPTISTA P,COELHO C,BEIRO J N M,MEIRELES A.Vitrectomy outcomes in eyes with tractional diabetic macular edema［J］．Ophthalmic Res,2019,61(2):94-99.
［5］　GUNAY B O,ERDOGAN G.Evaluation of macular changes in the long term after pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema［J］．Ophthalmologica,2021,244(3):237-244.
［6］　CAKIR A,ERDEN B,BOLUKBASI S,SEVER O,ERKUL S O,OSMANBASOGLU O A,et al.Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema:one-year results［J］．Arq Bras Oftalmol,2020,83(5):396-401.
［7］　GEDAR T O M,KANRA A Y,BROMAND M N,KILIC T G,ARI Y S,TURKMEN I,et al.Effectiveness of intravitreal ranibizumab in nonvitrectomized and vitrectomized eyes with diabetic macular edema:a two-year retrospective analysis［J］．J Ophthalmol,2020,2020:2561251.
［8］　CHEN Y Y,CHEN P Y,CHEN F T,CHEN Y J,WANG J K.Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema［J］．Int Ophthalmol,2018,38(1):293-299.
［9］　KOYANAGI Y,YOSHIDA S,KOBAYASHI Y,KUBO Y,YAMAGUCHI M,NAKAMA T,et al.Comparison of the effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized and nonvitrectomized eyes［J］．Ophthalmologica,2016,236(2):67-73.
［10］　BRESSLER S B,MELIA M,GLASSMAN A R,ALMUKHTAR T,JAMPOL L M,SHAMI M,et al.Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy prior to anti-vascular endothelial growth factor therapy ［J］．Retina,2015,35(12):2516-2528.
［11］　OKAMOTO Y,OKAMOTO F,HIRAOKA T,OSHIKA T.Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy［J］．Jpn J Ophthalmol,2014,58(4):369-374.
［12］　YANYALI A,AYTUG B,HOROZOGLU F,NOHUTCU A F.Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes［J］．Am J Ophthalmol,2007,144(1):124-126.
［13］　TRAN T H C,VERDUN S,LE R J F,UZZAN J,MILAZZO S,KODJIKIAN L,et al.Two-year outcome of aflibercept intravitreal injection in vitrectomized eyes with diabetic macular edema［J］．Clin Ophthalmol,2022,16:603-609.
［14］　TRAN T H C,ERGINAY A,VERDUN S,FOURMAUX E,LE R J F,UZZAN J,et al.One-year outcome of aflibercept intravitreal injection in vitrectomized eyes with diabetic macular edema［J］．Clin Ophthalmol,2021,15:1971-1978.
［15］　LAUGESEN C S,OSTRI C,BRYNSKOV T,LUND-ANDERSEN H,LARSEN M,VORUM H,et al.Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes［J］．Acta Ophthalmol,2017,95(1):28-32.
［16］　TRKSEVEN K E,ERALIK N Y.Intravitreal ranibizumab versus aflibercept for diabetic macular edema in vitrectomized eyes:12 month results［J］．Semin Ophthalmol,2021,36(8):723-727.
［17］　NIWA Y,KAKINOKI M,SAWADA T,WANG X,OHJI M.Ranibizumab and aflibercept:intraocular pharmacokinetics and their effects on aqueous vegf level in vitrectomized and nonvitrectomized macaque eyes［J］．Invest Ophthalmol Vis Sci,2015,56(11):6501-6505.
［18］　PEARSON P A,HAINSWORTH D P,ASHTON P.Clearance and distribution of ciprofloxacin after intravitreal injection［J］．Retina,1993,13(4):326-330.
［19］　CHIN H S,PARK T S,MOON Y S,OH J H.Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes［J］．Retina,2005,25(5):556-560.
［20］　AMOAKU W M,SAKER S,STEWART E A.A review of therapies for diabetic macular oedema and rationale for combination therapy［J］．Eye (Lond),2015,29(9):1115-1130.
［21］　UNG C,BORKAR D S,YOUNG L H.Current and emerging treatment for diabetic macular edema［J］．Int Ophthalmol Clin,2017,57(4):165-177.
［22］　PAK K Y,CHOI B S,PARK S W,BYON I S,LEE J E.Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema:retrospective comparative analysis of an interventional case series［J］．Indian J Ophthalmol,2017,65(6):488-492.
［23］　WATANABE A,TSUZUKI A,ARAI K,GEKKA T,KOHZAKI K,TSUNEOKA H.Efficacy of intravitreal triamcinolone acetonide for diabetic macular edema after vitrectomy［J］．J Ocul Pharmacol Ther,2016,32(1):38-43.
［24］　SHIMONAGANO Y,DOI N,NODA Y,UEMURA A,SAKAMOTO T.Recurrence of diabetic macular edema after intravitreous injection of triamcinolone following vitrectomy［J］．Jpn J Ophthalmol,2007,51(4):278-284.
［25］　HONG J H,CHIANG C S,TSAO C Y,LIN P Y,WU C J,MCBRIDE W H.Can short-term administration of dexamethasone abrogate radiation-induced acute cytokine gene response in lung and modify subsequent molecular responses?［J］.Int J Radiat Oncol Biol Phys,2001,51(2):296-303.
［26］　MARASHI A,ZAZO A.Suprachoroidal injection of triamcinolone acetonide using a custom-made needle to treat diabetic macular edema post pars plana vitrectomy:a case series［J］．J Int Med Res,2022,50(4):3000605221089807.
［27］　SATO H,NAITO T,MATSUSHITA S,TAKEBAYASHI M,SHIOTA H.Efficacy of sub-Tenon’s capsule injection of triamcinolone acetonide for refractory diabetic macular edema after vitrectomy［J］．J Med Invest,2008,55(3-4):279-282.
［28］　KOGA T,MAWATARI Y,INUMARU J,FUKUSHIMA M,TANIHARA H.Trans-Tenon’s retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy［J］．Graefes Arch Clin Exp Ophthalmol,2005,243(12):1247-1252.
［29］　WANG J K,HUANG T L,CHANG P Y.Effect of dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes of Taiwanese patients with treatment-nave diabetic macular edema［J］．J Formos Med Assoc,2020,119(11):1619-1625.
［30］　EVIK S G,YILMAZ S,EVIK M T,AKALP F D,AVCI R.Comparison of the effect of intravitreal dexamethasone implant in vitrectomized and nonvitrectomized eyes for the treatment of diabetic macular edema［J］．J Ophthalmol,2018,2018:1757494.
［31］　MEDEIROS M D,ALKABES M,NAVARRO R,GARCIA A J,MATEO C,CORCSTEGUI B.Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema［J］．J Ocul Pharmacol Ther,2014,30(9):709-716.
［32］　BOYER D S,FABER D,GUPTA S,PATEL S S,TABANDEH H,LI X Y,et al.Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients［J］．Retina,2011,31(5):915-923.
［33］　SHAH A R,XI M,ABBEY A M,YONEKAWA Y,FAIA L J,HASSAN T S,et al.Short-term efficacy of intravitreal dexamethasone implant in vitrectomized eyes with recalcitrant diabetic macular edema and prior anti-vegf therapy［J］．J Ophthalmic Vis Res,2016,11(2):183-187.
［34］　ZDEMIR H B,HASANREISO GˇLU M,YKSEL M,ERTOP M,GRELIK G,ZDEK .Effectiveness of intravitreal dexamethasone implant treatment for diabetic macular edema in vitrectomized eyes［J］．Turk J Ophthalmol,2019,49(6):323-327.
［35］　ALTUN A,HACIMUSTAFAOGLU A M.Effect of dexamethasone implant on subfoveal choroidal thickness in early period in vitrectomized eyes with diabetic macular edema［J］．J Ophthalmol,2021,2021:8840689.
［36］　NAGAOKA T,KITAYA N,SUGAWARA R,YOKOTA H,MORI F,HIKICHI T,et al.Alteration of choroidal circulation in the foveal region in patients with type 2 diabetes［J］．Br J Ophthalmol,2004,88(8):1060-1063.
［37］　FRANZOLIN E,GUSSON E,PANOZZO G.The effect of pars plana vitrectomy with internal limiting membrane peeling on the durability of the intravitreal dexamethasone implant in the treatment of diabetic macular edema［J］．Am J Ophthalmol Case Rep,2022,26:101401.
［38］　WANG J K,HUANG T L,CHANG P Y,HO W T,HSU Y R,CHEN F T,et al.Comparison of intravitreal dexamethasone implant and ranibizumab in vitrectomized eyes with diabetic macular edema［J］．J Ophthalmol,2021,2021:8882539.
［39］　CAMPOCHIARO P A,BROWN D M,PEARSON A,CHEN S,BOYER D,RUIZ M J,et al.Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema［J］.Ophthalmology,2012,119(10):2125-2132.
［40］　AUGUSTIN A J,BOPP S,FECHNER M,HOLZ F G,SANDNER D,WINKGEN A M,et al.The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema［J］．Eur J Ophthalmol,2021,11206721211014728.
［41］　LA M A,HAWRAMI A,LAVIERS H,PATRA S,ZAMBARAKJI H.Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes［J］．Int J Ophthalmol,2018,11(12):1951-1956.
［42］　COELHO J,MALHEIRO L,MELO B J,MEIRELES A,PESSOA B.Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes［J］．Clin Ophthalmol,2019,13:1751-1759.
［43］　DORIN G.Subthreshold and micropulse diode laser photocoagulation［J］．Semin Ophthalmol,2003,18(3):147-153.
［44］　FRIZZIERO L,CALCIATI A,MIDENA G,TORRESIN T,PARROZZANI R,PILOTTO E,et al.Subthreshold micropulse laser modulates retinal neuroinflammatory biomarkers in diabetic macular edema［J］．J Clin Med,2021,10(14):3134.
［45］　MIDENA E,MICERA A,FRIZZIERO L,PILOTTO E,ESPOSITO G,BINI S.Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema［J］．Sci Rep,2019,9(1):10034.
［46］　BONFIGLIO V,REJDAK R,NOWOMIEJSKA K,ZWEIFEL S A,JUSTUS W M R,ROMANO G L,et al.Efficacy and safety of subthreshold micropulse yellow laser for persistent diabetic macular edema after vitrectomy:a pilot study［J］．Front Pharmacol,2022,13:832448.
［47］　AOKI R,HATANO M,HIGASHIJIMA F,YOSHIMOTO T,MIKUNI M,OGATA T,et al.Intravitreal tissue plasminogen activator injection for treatment-resistant diabetic macular edema of the vitrectomized eye［J］．Case Rep Ophthalmol,2021,12(3):841-847.
［48］　XU Y,YOU Y,DU W,ZHAO C,LI J,MAO J,et al.Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade［J］．Invest Ophthalmol Vis Sci,2012,53(9):5221-5226.
［49］　YAO T T,YANG Y,JIN X L,WANG Y X,ZHOU Y L,XU A J,et al.Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy:a randomized controlled pilot study［J］．Acta Ophthalmol,2020,98(7):e795-e800.

相似文献/References:

[1]董敬远 刘瑶 吴晓艳.玻璃体切割联合白内障手术治疗增生性糖尿病视网膜病变[J].眼科新进展,2012,32(5):000.
[2]张楚 邹玉平 邹秀兰 徐哲 王泳.内窥镜引导玻璃体视网膜手术治疗伴有角膜混浊的外伤性视网膜脱离[J].眼科新进展,2012,32(6):000.
[3]刘刚 马英慧 贾万程.玻璃体切割术联合视网膜光凝或内界膜剥除术治疗黄斑裂孔性视网膜脱离的疗效分析[J].眼科新进展,2012,32(7):000.
[4]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[5]刘敬花 李松峰 卢海.23G微创玻璃体切割术在增生性糖尿病视网膜病变治疗中的应用[J].眼科新进展,2012,32(11):000.
[6]王蕊 王兴利 王一.玻璃体切割术治疗球内金属异物并发眼内炎的玻璃体腔填充物的选择[J].眼科新进展,2012,32(11):000.
[7]杨铮 陈彬川 周瑞雅.玻璃体手术后高眼压及其处理[J].眼科新进展,2012,32(11):000.
[8]陈吉婷 李学喜 王志军.两种手术方式取出眼后段磁性异物的对比研究[J].眼科新进展,2012,32(11):000.
[9]张保松.复杂开放性眼外伤手术疗效及其相关影响因素分析[J].眼科新进展,2012,32(12):000.
[10]杜新华 吴强 宋蓓雯 陈永东 陈颖 罗兰.非外伤性玻璃体积血的发病原因及疗效分析[J].眼科新进展,2013,33(1):000.
[11]沈强 张学东.糖尿病黄斑水肿的发病机制及治疗进展[J].眼科新进展,2012,32(2):000.
[12]朱婷婷,王权,姜彩辉.糖尿病黄斑水肿治疗新进展[J].眼科新进展,2019,39(3):296.[doi:10.13389/j.cnki.rao.2019.0067]
　ZHU Ting-Ting,WANG Quan,JIANG Cai-Hui.Recent research advances in the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(3):296.[doi:10.13389/j.cnki.rao.2019.0067]

备注/Memo

备注/Memo:
吉林省自然科学基金项目（编号：20200201379JC）；吉林省教育厅科学技术项目（编号：JJKH20190046KJ）
更新日期/Last Update: 2023-03-05